Cargando…
Status of the Current Treatment Options and Potential Future Targets in Uterine Leiomyosarcoma: A Review
SIMPLE SUMMARY: Uterine leiomyosarcoma (uLMS) is a rare and aggressive mesenchymal malignancy. Although approximately 65% of patients are diagnosed in stage I, more than 50% have relapsed disease, and effective therapies for recurrent and advanced cases are limited. This review summarizes the curren...
Autores principales: | Asano, Hiroshi, Isoe, Toshiyuki, Ito, Yoichi M., Nishimoto, Naoki, Watanabe, Yudai, Yokoshiki, Saki, Watari, Hidemichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909836/ https://www.ncbi.nlm.nih.gov/pubmed/35267488 http://dx.doi.org/10.3390/cancers14051180 |
Ejemplares similares
-
Molecular Targets and Emerging Therapeutic Options for Uterine Leiomyosarcoma
por: Miller, Heather, et al.
Publicado: (2016) -
Preoperative Differentiation of Uterine Leiomyomas and Leiomyosarcomas: Current Possibilities and Future Directions
por: Żak, Klaudia, et al.
Publicado: (2022) -
Uterine Leiomyosarcoma
por: Byar, Katherine L., et al.
Publicado: (2022) -
Current Chemotherapy and Potential New Targets in Uterine Leiomyosarcoma
por: Momtahen, Shabnam, et al.
Publicado: (2016) -
Adjuvant chemotherapy for early-stage cervical cancer
por: Asano, Hiroshi, et al.
Publicado: (2016)